ARTICLE | Financial News
Sequoia China leads seed round for next-gen T cell therapy play
August 30, 2018 11:00 AM UTC
RootPath Inc. (Cambridge, Mass.) raised $7 million in a seed round led by Sequoia China. Fellow new investors Volcanics Venture, Baidu Ventures and Nest.Bio Ventures also participated.
Co-founder and CEO Xi Chen told BioCentury the funding provides a cash runway of 12-18 months...